Abstract
Background In December 2019, a novel coronavirus disease (COVID-19) broke out in Wuhan, China, however, the factors affecting the mortality remain unclear.
Methods A cross-sectional study based on 32 days (from January 21, 2020 to February 21, 2020) of data that were shared by China National Health Commission and China Weather Net. We compared the difference in the growth rate of confirmed cases and the mortality of confirmed cases and severe cases before and after “Fangcang, Huoshenshan, and Leishenshan” makeshift hospitals (MSHs) were put into use. We also studied whether air temperature (AT) could affect the above outcomes of COVID-19 patients.
Results Mann-Whitney U test was performed to compare the difference in mortality before and after the use of makeshift hospitals. Eight day after the use of makeshift hospitals, the mortality of confirmed cases was significantly decreased both in Wuhan (U = 1, P < .001) and Hubei (U = 0, P < .001), while in non-Hubei regions, as a contrast, the mortality of confirmed cases remained unchanged (U = 40, P = .139). However, the decrease in the mortality in non-Hubei regions also became significant until sixteen days after the use of makeshift hospitals (U = 73, P = .039). Mortality of confirmed cases was also found to be significantly correlated with temperature both in Wuhan (r = .441, P = .012) and Hubei (r = .440, P = .012) by performing Spearman’s analysis.
Conclusions Our findings indicated that both the use of makeshift hospitals and the rise of temperature were beneficial to the survival of COVID-19 patients. Subsequent studies are suggested to further explore other factors that may affect the mortality of COVID-19, so that this epidemic can be better contained.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
1. National Natural Science Foundation of China (No. 81970583) 2. Nature Science Foundation of Jiangxi Province (No. 20181BAB205016)
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos